Scientists have discovered a new treatment for leukemia that has the potential to provide a much better alternative to existing methods of treatment. The cancer breakthrough allows us to fight cancer without killing any of the healthy cells.
Researchers from Walter and Eliza Hall Institute in Melbourne are responsible for developing the new treatment, which could soon be available for one of the most aggressive cancers: acute myeloid leukemia (AML).
This news is incredibly promising, but it will need to undergo rigorous testing before it can get approval from the Food and Drug Administration, as is the case with any medical breakthrough. Although there are no guarantees that this treatment will get approved or implemented, the discovery is certainly exciting news for the medical community.
What exactly does the treatment involve?
The scientists identified a protein that is crucial to stopping the spread of the blood cancer called Hhex protein. When they are able to effectively cut off production of the Hhex protein in laboratory conditions, the results show that cancer can be stopped from spreading uncontrollably.
The use of the Hhex protein is especially beneficial because it is not required in healthy blood cells. This makes it a great alternative treatment to typical AML treatments that normally have damaging side-effects.
“Most existing treatments for AML are not cancer cell-specific, and, unfortunately, kill off healthy cells in the process,” said one of the studies researchers, Matt McCormack. “Hhex is only essential for the leukaemic cells, meaning we could target and treat leukemia without toxic effects on normal cells, avoiding many of the serious side-effects that come with standard cancer treatments.”
The researchers are now looking at whether or not the same results can be recreated in humans.
“Hhex only regulates a small number of genes and is dispensable for normal blood cells,” stated McCormack. “This gives us a rare opportunity to kill AML cells without causing many side-effects. We now hope to identify the critical regions of the Hhex protein that enable it to function, which will allow us to design much-needed new drugs to treat AML.”
Time will tell if this treatment becomes readily available for cancer patients. But if clinical trials prove to be successful then widespread use may be just a few years away.